How should prostatitis be diagnosed and managed in its acute bacterial, chronic bacterial, and chronic pelvic pain forms?

Prostatitis: Diagnosis and Management

Acute Bacterial Prostatitis (ABP)

For acute bacterial prostatitis, obtain midstream urine culture and blood cultures immediately, avoid prostatic massage, and initiate empiric fluoroquinolone therapy while awaiting culture results. 1

Diagnostic Approach for ABP

• Do NOT perform prostatic massage - this is a strong contraindication in ABP 1
• Obtain midstream urine dipstick checking for nitrites and leukocytes 1
• Collect midstream urine culture to guide antibiotic selection 1
• Draw blood cultures and complete blood count 1
• Consider transrectal ultrasound only in selected cases to rule out prostatic abscess 1

The diagnosis is primarily clinical, based on acute onset of pelvic pain, urinary symptoms (dysuria, frequency, retention), and systemic symptoms (fever, chills, malaise). Physical examination reveals a tender, enlarged, or boggy prostate on digital rectal examination. 2

Treatment of ABP

Outpatient Management (most patients):

• Fluoroquinolones are first-line: ciprofloxacin or levofloxacin for 2-4 weeks 3, 4
• Alternative: trimethoprim-sulfamethoxazole if pathogen is susceptible 3
• Doxycycline can be used as alternative therapy 3

Inpatient Management (systemically ill, unable to void, unable to tolerate oral intake, or risk factors for resistance):

• Broad-spectrum IV antibiotics: ceftriaxone plus doxycycline 2
• Or piperacillin-tazobactam 2
• Or third-generation cephalosporins with aminoglycoside 5
• For multidrug-resistant pathogens: consider meropenem or piperacillin-tazobactam 5

The causative organisms are predominantly Enterobacterales (E. coli most common), with increasing recognition of Enterococci. 1, 5 Approximately 10% of ABP cases progress to chronic bacterial prostatitis. 4

---

Chronic Bacterial Prostatitis (CBP)

For chronic bacterial prostatitis, perform the Meares-Stamey 4-glass test (or modified 2-glass test) to confirm prostatic localization, test for atypical pathogens including Chlamydia and Mycoplasma, and treat with fluoroquinolones for minimum 4 weeks up to 12 weeks. 1, 3

Diagnostic Approach for CBP

• Perform the Meares-Stamey 4-glass test (or simplified 2-glass test) - this is the gold standard for localizing infection to the prostate 1
• Test specifically for atypical pathogens: Chlamydia trachomatis and Mycoplasma species 1
• Do NOT routinely use ejaculate analysis alone for diagnosis 1
• Consider transrectal ultrasound in selected cases 1

CBP encompasses a broader spectrum of organisms than ABP, including atypical microorganisms and sexually transmitted pathogens. 1, 5 The condition is characterized by recurrent urinary tract infections with the same uropathogen, pelvic pain, urinary symptoms, and ejaculatory pain. 6

Treatment of CBP

Antimicrobial Therapy:

• Fluoroquinolones remain first-line: ciprofloxacin or levofloxacin for minimum 4 weeks, up to 12 weeks 3, 4, 6
• Fluoroquinolones achieve superior prostatic penetration and cure approximately 70% of cases 5
• Alternative if susceptible: trimethoprim-sulfamethoxazole 3
• For Chlamydial prostatitis: macrolides (azithromycin) are more effective than fluoroquinolones 5
• For intracellular pathogens: doxycycline or macrolides 5
• For fluoroquinolone-resistant organisms: consider fosfomycin or aminoglycosides 3, 5

Critical Caveat: Increasing fluoroquinolone resistance is a significant clinical problem, necessitating culture-guided therapy. 4 Biofilm formation by uropathogens may facilitate progression to chronic infection. 4

---

Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

For CP/CPPS, recognize this is a diagnosis of exclusion affecting 90% of prostatitis patients; initiate a 4-6 week trial of fluoroquinolones (most effective if started early), then add alpha-blockers for urinary symptoms and anti-inflammatories for pain, with referral to pelvic floor physical therapy if inadequate response. 7, 6

Diagnostic Approach for CP/CPPS

This is a diagnosis of exclusion - fewer than 10% of prostatitis cases have confirmed bacterial infection. 1 The condition is defined by pelvic pain for more than 3 of the previous 6 months, urinary symptoms, and painful ejaculation, without documented urinary tract infections from uropathogens. 6

• Rule out bacterial prostatitis through cultures when symptomatic 6
• If no history of documented UTIs with uropathogens, perform prostatic localization cultures (Meares-Stamey test) to confirm absence of infection 6
• Use validated questionnaires: NIH Chronic Prostatitis Symptom Index (NIH-CPSI) to inventory symptoms and monitor treatment response 8
• Success is defined as 25% or 6-point reduction in NIH-CPSI score 8

The UPOINTS classification system can guide phenotype-specific treatment: Urinary, Psychosocial, Organ-specific, Infection, Neurological, Muscle Tension/Tenderness, and Sexual dysfunction domains. 5

Treatment Algorithm for CP/CPPS

First-Line (4-6 weeks):

• Fluoroquinolone trial for 4-6 weeks - provides relief in 50% of men, more efficacious if prescribed soon after symptom onset 6
• May repeat if initial course provides relief 6

Second-Line (if inadequate response):

• Alpha-blockers (e.g., tamsulosin) for urinary symptoms - particularly if functional subvesical obstruction is documented or suspected 6, 9
• Anti-inflammatory agents/NSAIDs for pain symptoms 6
• Pelvic floor physical therapy/biofeedback - potentially more effective than pharmacotherapy but requires randomized trials for confirmation 6

Third-Line Options:

• 5-alpha reductase inhibitors 6
• Quercetin (phytotherapy) 6, 5
• Pollen extract (Cernilton) 6, 5
• Serenoa repens extract 5

Multimodal Therapy: The combination of alpha-blockers, antibiotics, and anti-inflammatories shows better symptom control than single-drug treatment. 5

Behavioral/Lifestyle Modifications: 7

• Dietary changes: avoid spicy foods, coffee, tea, chili, and alcohol (47% of patients report food sensitivities)
• Increase fruits, vegetables, fiber (docusate, psyllium, water)
• Aerobic exercise
• Consider referral to dietician

Treatment-Refractory Patients:

• Transurethral microwave therapy 6
• Consider probiotics and evaluation of intestinal dysbiosis 5

Important Clinical Considerations

Common Pitfalls:

• The pathophysiology likely involves an infectious/inflammatory initiator causing neurological injury and pelvic floor dysfunction with increased muscle tone 6
• This is a chronic pain condition, not simply an infection - treatment expectations must be realistic 7, 8
• Sexual dysfunction (erectile, ejaculatory, libido loss) occurs in 46-92% of cases and significantly impacts quality of life 5
• CP/CPPS does NOT predispose to prostate cancer but may be associated with male infertility 8
• Monitor for mental health effects 8

The evidence for CP/CPPS treatments is limited - most modalities have variable proven benefit without robust supporting evidence. 7, 8 Treatment must be individualized based on phenotype using the UPOINTS system, with multimodal therapy addressing pain, urinary symptoms, pelvic floor dysfunction, and psychosocial factors simultaneously.